TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation
Michael D. Oberst(National Institutes of Health), Kathleen Kelly(National Cancer Institute)
Cited by 50
Related Papers
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|312
Prostate Epithelial Pten/TP53 Loss Leads to Transformation of Multipotential Progenitors and Epithelial to Mesenchymal Transition
|American Journal Of Pathology|2011|100